IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
Phase 2 biotech developing therapies for RAS/MAPK pathway-driven cancers.
Industry: Health Care
Latest Trade: $1.89 0.00 (0.0%)
First Day Return: +8.9%
Return from IPO: -88.2%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 06/25/2021 |
Offer Price | $16.00 |
Price Range $14.00 - $16.00 | |
Offer Shares (mm) | 18.8 |
Deal Size ($mm) | $300 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 07/15/2021 |
Offer Price | $16.00 |
Price Range $14.00 - $16.00 | |
Offer Shares (mm) | 18.8 |
Deal Size ($mm) | $300 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
J.P. Morgan |
Morgan Stanley |
more |
Company Data | |
---|---|
Headquarters | San Diego, CA, United States |
Founded | 2018 |
Employees | 102 |
Website www.erasca.com |